![]() |
|
William B. Jones, senior vice president of pharmaceutical development at Corvus Pharmaceuticals, discusses CDMO selection for the company’s CPI-006 antibody program, which is currently under development as an oncology drug and investigation as a therapeutic for immune disorders and infectious diseases.
|